Loading
SMARCA4 is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
ATPase involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating the calcium-dependent release of a repressor complex and the recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by SMARCA4-dependent recruitment of a phospho-RB1-HDAC repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. Location: Nucleus (UniProt). Locus 19p13.2 (HGNC).
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Non-small-cell lung cancer | 6-10% | Truncating and missense mutation (class 1 and class 2) | cBioPortal: 228 of 2,653, 8.6%, in luad_mskcc_2023_met_organotropism; 92 of 915, 10.1%, in lung_msk_2017; 46 of 566, 8.1%, in luad_tcga_pan_can_atlas_2018; 11 of 110, 10.0%, in luad_cptac_2020; 27 of 240, 11.2%, in nsclc_pd1_msk_2018; 17 of 484, 3.5%, in lusc_tcga_pan_can_atlas_2018; 8 of 302, 2.6%, in luad_oncosg_2020. In 4,813 patients, 407, 8%, carried a SMARCA4 alteration (Schoenfeld 2020). | cBioPortal (TCGA) |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"SMARCA4" OR ABSTRACT:"SMARCA4" OR TITLE:"SWI/SNF related BAF chromatin remodeling complex subunit ATPase 4" OR ABSTRACT:"SWI/SNF related BAF chromatin remodeling complex subunit ATPase 4" OR TITLE:"SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4" OR ABSTRACT:"SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4" OR TITLE:"hSNF2b" OR ABSTRACT:"hSNF2b" OR TITLE:"BRG1" OR ABSTRACT:"BRG1" OR TITLE:"BAF190" OR ABSTRACT:"BAF190") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SMARCA4, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/smarca4.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/smarca4.json. Licence CC BY-NC 4.0.